Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12932352 | 0.96 | HCRTR1 (0.55) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL382980 | 0.90 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL10107157 | 0.90 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL1066934 | 0.88 | HCRTR1 (0.49) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL10107160 | 0.86 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL1066135 | 0.86 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL385013 | 0.84 | HCRTR1 (0.51) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL10107126 | 0.84 | HCRTR1 (0.51) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL16433615 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2KDM4ELMNAABL1 | |
| SCHEMBL16433616 | 0.83 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ELMNAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101768-B2 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-7868178-B2 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20090143443-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7485727-B2 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20080319003-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080045569-A1 | Cyclic Amine Compound and Pest Control Agent | NIPPON SODA CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045569-A1 | Cyclic Amine Compound and Pest Control Agent | H1-0, H1-2, H1-4 | HCRTR1 41/4885HCRTR2 202/4885KDM4E 373/4885 |
| US-20090143443-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | TAAR1, CBR3, CBR1 | HCRTR1 13/4885HCRTR2 60/4885KDM4E 1169/4885 |
| US-20080319003-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | H1-0, H1-2, H1-4 | HCRTR1 50/4885HCRTR2 260/4885KDM4E 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.